Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Free Cash Flow of -$14.7 million for Q1 2026, up 66.35% year-over-year from -$8.9 million in Q1 2025, and up 14.52% quarter-over-quarter from -$17.2 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Free Cash Flow for 17 consecutive years, with -$14.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 66.35% year-over-year to -$14.7 million; the TTM figure through Mar 2026 stood at -$38.8 million (up 76.97% YoY), while the FY2025 annual figure was -$67.9 million, up 62.27% from the prior year.
- Free Cash Flow rose to -$14.7 million in Q1 2026 per LXRX's latest filing, from -$17.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $17.0 million in Q2 2025 and bottomed at -$55.1 million in Q1 2024.
- Historically, Free Cash Flow has averaged -$30.3 million across 5 years, with a median of -$24.4 million in 2022.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 121.56% — and 2025, when it soared 134.83%.
- Lexicon Pharmaceuticals' Free Cash Flow stood at -$22.8 million in 2022, then slumped by 121.56% to -$50.5 million in 2023, then soared by 56.55% to -$22.0 million in 2024, then rose by 21.54% to -$17.2 million in 2025, then rose by 14.52% to -$14.7 million in 2026.
- Business Quant data shows LXRX's Free Cash Flow at -$14.7 million in Q1 2026, -$17.2 million in Q4 2025, and -$23.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.19 Mn |
| Jun 30, 2026 | -9.19 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Dec 31, 2024 | -21.97 Mn |
| Dec 31, 2024 | -21.97 Mn |
| Sep 30, 2024 | -53.93 Mn |
| Sep 30, 2024 | -53.93 Mn |
| Jun 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.79 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Mar 31, 2024 | -55.13 Mn |